Disparities in allo-HCT access for AML persist, particularly among non-Hispanic Black patients and those with lower socioeconomic status, despite increased donor availability. Financial burdens and ...
ACCESS trial results at the 2026 Tandem Meetings reinforce mismatched unrelated donors as safe, effective and well-tolerated ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Three-year overall survival (OS) and GVHD-free, ...
Prospective Multicenter Diagnostic Performance of Technologist-Performed Screening Breast Ultrasound After Tomosynthesis in Women With Dense Breasts (the DBTUST) We studied 2,391 single class I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results